Federal Minister of Health tables the 2017 Annual Report of the Patented Medicine Prices Review Board
OTTAWA, Aug. 22, 2018 /CNW/ - The Honourable Ginette Petitpas Taylor, Federal Minister of Health, today tabled the 2017 Annual Report of the Patented Medicine Prices Review Board (PMPRB) with the Clerks of the House of Commons and the Senate.
The PMPRB is an independent quasi-judicial body that protects the interests of Canadian consumers by ensuring the prices of patented medicines sold in Canada are not excessive, and provides stakeholders with price, cost, and utilization information to help them make timely and knowledgeable medicine pricing, purchasing, and reimbursement decisions.
The 2017 Annual Report sets out detailed information on the PMPRB's regulatory activities; patentees' compliance with the Board's pricing guidelines; sales and price trends of patented medicines sold in Canada, including international price comparisons, trends in all medicine expenditures, and spending on pharmaceutical research and development.
Quick Facts
In 2017, Canadian patented medicines prices were lower than prices in Switzerland, Germany and the United States but higher than prices in the UK, France, Italy and Sweden.
Sales of patented medicines increased in 2017 by 7.6% to $16.8 billion.
1,391 patented medicines for human use were reported to the PMPRB, including 80 new medicines.
The R&D-to-sales ratio of pharmaceutical patentees in Canada was 4.1%, a decrease from 4.4% in 2016.
There were 122 ongoing investigations into possible excessive patented medicine pricing as of March 31, 2018.
In 2017, patentees agreed to pay back $35 Million in excess revenues to the Government of Canada through Voluntary Compliance Undertakings entered into with the PMPRB.
High-cost medicines represent an increasingly significant share of total patented medicine sales, rising steeply from 7.6% in 2006 to a remarkable 41.6% in 2017.
Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on March 28, 2024.
One individual was...
Paladin Labs Inc., a subsidiary of Endo International plc , today announced Health Canada's approval of WAKIX® (pitolisant hydrochloride tablets) for the treatment of excessive daytime sleepiness (EDS) or cataplexy in pediatric patients aged 6 years...
Sirona Biochem Corp. ("Sirona") announces the voting results from its Annual General Meeting of Shareholders (the "Meeting"), held in Vancouver, British Columbia on March 28, 2024. The total number of shares represented by shareholders present in...
The Doctors Company, the nation's largest physician-owned medical malpractice insurer, announced today that it has approved a 2024 premium dividend of approximately $14.7 million, bringing the total of declared dividends to date to $470 million....
Northern Virginia Oral, Maxillofacial & Implant Surgery ("NOVA OMS") has learned of a data security incident that may have impacted data belonging to certain patients and guarantors.
On October 5, 2023, NOVA OMS became aware of unusual activity on...
The Journey Venture Studio announced today a strategic collaboration with Valleywise Health, a comprehensive healthcare system with locations throughout the Phoenix metro area. In pursuit of fostering innovation, this collaboration is set to...